Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency.

Wasserman, Richard L; Melamed, Isaac R; Stein, Mark R; Jolles, Stephen; Norton, Miranda; Moy, James N

Wasserman, Richard L; Melamed, Isaac R; Stein, Mark R; Jolles, Stephen; Norton, Miranda; Moy, James N.

Afiliação

Wasserman RL; Allergy Partners of North Texas Research, Dallas, TX, USA.
Melamed IR; IMMUNOe International Research Centers, Centennial, CO, USA.
Stein MR; Allergy Associates of the Palm Beaches, North Palm Beach, FL, USA.
Jolles S; Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK.
Norton M; Bio Products Laboratory Ltd., Dagger Lane, Elstree, Hertfordshire, UK. miranda.norton@bpl.co.uk.
Moy JN; Section of Allergy and Immunology, Department of Immunology and Microbiology, Rush University Medical Center, Chicago, IL, USA.

J Clin Immunol ; 37(6): 613, 2017 08.

Article em En | MEDLINE | ID: mdl-28714047

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Clin Immunol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google